Yes, buprenorphine/naloxone is a federally controlled substance. It is classified as a Schedule III narcotic under the Controlled Substances Act, meaning it has an accepted medical use but carries some potential for abuse and dependence. This classification affects how the medication is prescribed, refilled, and carried across borders.
Why It’s Classified as Schedule III
The Drug Enforcement Administration (DEA) rescheduled buprenorphine from Schedule V to Schedule III in 2002, after evaluating eight factors including its abuse potential, pharmacological effects, and dependence liability. The DEA determined that buprenorphine has a lower potential for abuse than Schedule I and II drugs (which include heroin and methadone, respectively), but that misuse can lead to moderate or low physical dependence and high psychological dependence. Every product containing buprenorphine, including the combination with naloxone, falls under this Schedule III classification.
For context, Schedule III is a middle tier. Schedule I substances have no accepted medical use and high abuse potential. Schedule II includes drugs like oxycodone and methadone, which carry stricter prescribing rules. Schedule III drugs like buprenorphine are considered less prone to misuse than those categories but still require regulatory controls and carry criminal penalties for illegal handling.
What Naloxone Does in the Combination
Naloxone is included specifically to discourage misuse of the medication. When you take buprenorphine/naloxone as directed (dissolved under the tongue), buprenorphine absorbs well into your system at about 35% to 55% bioavailability, while naloxone barely absorbs at all, under 10%. So under normal use, the naloxone component has almost no effect on how the medication works.
The deterrent kicks in if someone tries to crush and inject the tablets. In that scenario, naloxone absorbs fully and blocks the opioid effects of buprenorphine, triggering withdrawal symptoms instead of any high. Clinical studies have confirmed that injecting the combination product precipitates withdrawal in opioid-dependent individuals. Research published in Frontiers in Psychiatry found that naloxone produces “almost complete attenuation” of the rewarding and reinforcing effects of buprenorphine when both are given intravenously. This abuse-deterrent design is one reason buprenorphine/naloxone remains at Schedule III rather than being moved to a more restrictive category.
How Schedule III Affects Your Prescription
The Schedule III classification comes with specific rules about how you receive the medication. Federal law allows a buprenorphine/naloxone prescription to be refilled up to five times, and the prescription expires six months after it was written. After that, you need a new prescription from your provider. This is notably more flexible than Schedule II medications like methadone, which cannot be refilled at all and require a new prescription each time.
A major change came in 2023 with the Consolidated Appropriations Act, which eliminated the old “X-waiver” requirement. Previously, doctors needed a special federal waiver and faced limits on how many patients they could treat with buprenorphine. Now, any practitioner with a standard DEA registration can prescribe it for opioid use disorder, with no patient caps. This change does not apply to methadone, which still requires dispensing through specialized clinics.
Telehealth Prescribing
Because buprenorphine is Schedule III rather than Schedule II, it benefits from broader telehealth prescribing options. DEA-registered practitioners can prescribe it through audio-video telemedicine encounters without ever conducting an in-person evaluation first. For opioid use disorder treatment specifically, prescribers can even use audio-only phone calls. The DEA extended these telemedicine flexibilities through the end of 2025, and two final rules published in January 2025 established more permanent pathways for telehealth prescribing going forward.
Legal Protections for Patients
Taking a controlled substance as prescribed does not make you legally vulnerable in most situations. The Americans with Disabilities Act protects people in recovery from opioid use disorder who take prescribed medication, including buprenorphine/naloxone. This means an employer generally cannot refuse to hire you, fire you, or take other negative action because a drug test shows you are taking medication prescribed by your doctor for a valid purpose. These protections extend to social services agencies, courts, medical facilities, schools, child welfare systems, and homeless shelters.
Traveling With Buprenorphine/Naloxone
Domestic travel within the United States is straightforward: keep the medication in its original labeled container and carry your prescription information. International travel requires more preparation. Many countries allow travelers to bring a 30-day supply of controlled medications but require a prescription or medical certificate from your provider. Some countries restrict or prohibit certain controlled substances entirely, which could result in confiscation, penalties, or even jail time.
Before any international trip, check with the embassy of your destination country and any layover countries. Ask your prescriber for a letter describing your condition and treatment plan. Keep medications in their original containers with clear labels showing your full name, your provider’s name, the generic and brand drug names, and the exact dosage. Carry copies of your written prescription as well.